Vanderbilt Health’s renowned surgeon Seth Karp is stepping down after 15 transformative years to assume top roles at Boston’s leading cancer and transplant institutions. Karp will leave his positions as System Surgeon-in-Chief and Chair of the Section of Surgical Sciences at Vanderbilt Health on Oct. 15 to become Chair of the Roberta and Stephen R. Weiner Department of Surgery at Beth Israel Deaconess Medical Center and Surgeon-in-Chief at Dana-Farber Cancer Institute.
This leadership transition comes as Vanderbilt prepares to launch a national search for Karp’s successor, expected to be finalized after Jan. 1, 2027, under the incoming Dean and CEO of Vanderbilt Health. In the meantime, President and CEO Jeff Balser, MD, PhD, is working closely with Karp and department leaders to appoint interim leadership for the Section of Surgical Sciences.
Seth Karp’s Legacy: Transforming Transplant and Surgery at Vanderbilt
Seth Karp’s departure marks the end of an era defined by clinical excellence, groundbreaking research, and unmatched growth at Vanderbilt’s transplant and surgical programs. When Karp joined Vanderbilt in July 2011 as Director of the Transplant Center and Liver Transplant Program, the center was already strong but not yet a global leader. Under his leadership, the center performed an astonishing 960 solid organ transplants by 2025, becoming the world’s top program for solid organ transplantation.
Karp helped Vanderbilt’s transplant milestones surge past 1,000 heart transplants and 2,000 liver transplants by 2017. The heart transplant program has since held its place as the global leader by volume, and the Liver Transplant Program marked its 3,000th transplant in 2024. His drive as a liver and pancreas transplant surgeon and administrator has saved thousands of lives and elevated Vanderbilt’s national prominence.
Since 2015, Karp broadened his impact as Chair of the Department of Surgery, overseeing divisions including General Surgery, Hepatobiliary Surgery, Surgical Oncology, Kidney and Pancreas Surgery, Trauma, and Vascular Surgery. In 2018, he was named Chair of the Section of Surgical Sciences and System Surgeon-in-Chief, leading Vanderbilt’s surgical strategy across clinical care, research, and education.
Boston Calling: A Full-Circle Return
Karp’s decision to relocate to Boston is closely tied to family, enabling him and his wife, Lauren, to be near their adult children and extended family in the Northeast. His career historically began in Boston, where he trained and worked at Harvard University, Harvard-MIT Health Sciences and Technology, Brigham and Women’s Hospital, and Beth Israel Deaconess Medical Center—the very institution he will now lead in surgery.
“Working at Vanderbilt has been the opportunity of a lifetime. I am enormously grateful to all my colleagues who helped create a unique place where clinical care, research, and education merge to benefit patients,” Karp said. “This next chapter will allow me to continue making a difference while rejoining family in the Northeast.”
Impact Beyond Vanderbilt: National Leadership in Transplant Policy
Karp is widely respected in the transplantation field nationally. He has held leadership roles with the American Society of Transplant Surgeons and served on the United Network for Organ Sharing (UNOS) Board of Directors. His advocacy efforts include landmark testimonies before U.S. congressional committees urging reform of organ procurement organizations to boost transplant organ availability.
His work shaped crucial UNOS directives and propelled calls for stricter performance standards, efforts with broad implications for transplant patients nationwide, including those in North Carolina and across the U.S.
What’s Next for Vanderbilt and Boston
Vanderbilt’s leadership praised Karp’s legacy as “legendary” and “one of our highest-impact chairs,” citing his success recruiting top talent and driving innovation through investment in new technologies and clinical programs. The transplant center’s record-breaking growth reflects Karp’s strategic focus on excellence and teamwork.
At Beth Israel Deaconess Medical Center, Karp’s new role will serve as a bridge to Dana-Farber Cancer Institute’s ambitious plan to advance cancer care with a new freestanding inpatient hospital for adults—the only one of its kind in the region.
For patients and families battling organ failure and cancer, Karp’s move signals promising advances ahead. With his proven record of leadership, innovation, and compassion, both Vanderbilt Health and Boston’s cancer and transplant communities will continue evolving rapidly in 2026 and beyond.
Jeff Balser, MD, PhD, President & CEO of Vanderbilt Health: “Seth will be remembered as a legendary leader and one of our highest-impact chairs. We will miss him professionally and personally.”
The NC Voice will monitor developments at both Vanderbilt and Boston institutions as these world-class surgical programs advance health care on the national stage.
